Coronary Revascularization and TAVR

Slides:



Advertisements
Similar presentations
Pablo M. Bedano M.D. Community Regional Cancer Care.
Advertisements

Rate of Obstructive Coronary Disease in Elective Diagnostic Cath Manesh R. Patel, MD Assistant Professor of Medicine Director Cath Lab Research – Duke.
Evaluation and Management of Asymptomatic Aortic Stenosis. Augusto Pichard, M.D. Director Innovation and Structural Heart Disease, Vice Chair, Medstar.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
Lessons from TAVR Randomized Trials and Registries E Murat Tuzcu, MD Professor of Medicine Cleveland Clinic Financial disclosures: None PARTNER Executive.
One stage coronary and peripheral intervention Pawel Buszman, MD, American Heart of Poland, Ustron Silesian Medical School, Katowice.
Rashad MAHMUDOV Central Hospital of Oilworkers, Baku-Azerbaijan
New guidelines for CABG
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.
PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.
Mitral Valve Surgery: Lessons from New York State Joanna Chikwe, MD Professor of Cardiovascular Surgery Icahn School of Medicine at Mount Sinai Chairman.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Role of Percutaneous coronary intervention (PCI) after thrombolytic therapy By Dr. Mohamed Mahros Assistant lecturer of cardiology Benha faculty of medicine.
Surgical approach of aortic valve disease associated with coronary artery disease Al Hussein Hussam Cernica D.R., Al Hussein S.M., Bud I.T., Ceteras D.M.
Revascularizaton of Ischemic DCM Percutaneous Revascularization and Hemodynamic Support Matthew R. Wolff, M.D. University of Wisconsin Disclosures: Cordis.
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.
Postoperative Delirium is Associated with Increased Operative and One Year Mortality in Patients Treated with Surgical and Transcatheter Aortic Valve Replacement.
A Contemporary Analysis of Pulmonary Hypertension in Patients Undergoing Mitral Valve Surgery: Is this a Risk Factor? Thank you to the society and panel.
GENDER DISPARITIES AMONG PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT Michael A. Gaglia, Jr.; Michael J. Lipinski; Rebecca Torguson; Jiaxiang.
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
Balloon-pump assisted Coronary Intervention Study BCIS-1 Simon Redwood Divaka Perera, Rod Stables, Martyn Thomas.
Asymptomatic mitral regurgitation When should you operate? Ben Bridgewater Cardiac surgeon and lead clinician, UHSM, Manchester Honorary Reader, Manchester.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.
Greater New York Geriatric Cardiology Consortium: Valve Disease in Older Adults Allan Schwartz, MD Columbia University Medical Center New York Presbyterian.
Minimalist Approach to T-AVR
Lessons from PARTNER I (A & B) CRT, Washington DC, Feb 5, 2012
Patients the Surgeon Should Refer for TAVR
TAVR in Patients With Chronic Kidney Disease
New Data from The PARTNER Trial
Extending the Boundaries of TAVR: Future Directions
Trans- catheter aortic valve replacement vs
Prof. Dr. med. Sigmund Silber Cardiology Practice and Hospital
Risk Stratification of Chest Pain: Best Practices
Pros and Cons of Radial Access
Are we ready to perform TAVI in Intermediate Risk Patients?
Updates From NOTION: The First All-Comer TAVR Trial
Critical Appraisal of the European CAS Trials
Revascularization in Patients With Left Ventricular Dysfunction:
TAVR in Patients with Chronic Lung Disease
TAVI Passed the Exam and is Ready for Clinical Use in Inoperable Patients Disclosures Research Funding and Speaking Honoraria: Edwards Lifesciences.
University of Pennsylvania
Giuseppe Tarantini MD, PhD
Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,
Early Feasibility Studies Investigator Perspective
Clinical need for determination of vulnerable plaques
Vinod H. Thourani, MD on behalf of The PARTNER Trial Investigators
Insights from the NCDR® STS/ACC TVT Registry.
Niv Ad, MD Chief, Cardiac Surgery Professor of Surgery, VCU
ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
Transradial Intervention as Access of Choice in STEMI
Balloon-Expandable Transcatheter Valve System : OUS Data
Fractional Flow Reserve Workshop
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Cardiovacular Research Technologies
Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
European Heart Association Journal 2007 April
PARTNER 2A Trial design: Intermediate-risk patients with aortic stenosis (STS PROM score 4-8%) were randomized to undergo either TAVR or SAVR, stratified.
SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)
How and why this study may change my practice ?
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Correlation between endothelial function and hypertension
Atlantic Cardiovascular Patient Outcomes Research Team
Lee A. Fleisher et al. JACC 2014;64:e77-e137
Presentation transcript:

Coronary Revascularization and TAVR Pichard, MD Director Cath Labs, Washington Hospital Center. Professor of Medicine (Cardiology), Georgetown University. Washington, DC.

Conflict of Interest Proctor for Edwards LifeSciences.

Do nothing, proceed with TAVR Revascularize a few weeks before TAVR What should we do with severe coronary obstructions in patients selected for TAVR? Do nothing, proceed with TAVR Revascularize a few weeks before TAVR Revascularize during or after TAVR

CAD in Patients with Severe AS. WHC: Ben-Dor et al CAD in Patients with Severe AS. WHC: Ben-Dor et al. Circulation 2010;122:S37-42 n= 302 patients referred to Partner Trial Patients with CAD had: higher STS and Euro scores, more females, more PVD, lower EF (all significant).

The Surgeons Experience with AVR and CAD

Mortality for AVR. STS Executive Summary 2010 www.sts.org <10% of patients had STS >10

Operative Mortality of AVR in 322 Patients >80 y. o Operative Mortality of AVR in 322 Patients >80 y.o. Gehlot et al, JThorCVSurgery 1996;111:1026-36

278 patients >80 years old discharged after AVR AVR + CABG Surviving Surgery. Gehlot et al, JThorCVSurgery 1996;111:1026-36 278 patients >80 years old discharged after AVR

Hybrid PCI and AVR. Byrne, Cohn et al Hybrid PCI and AVR. Byrne, Cohn et al. JACC 2005;45:14-18, AJC 2006;98:1501 PCI followed by minimally invasive AVR (the same day or within 14 days). 26 high risk patients

Conclusions from the Surgical Series Patients with severe CAD, that jeopardize significant amount of myocardium, need revascularization before or during AVR.

ESC Guidelines of The Task Force on VHD. Vahanian et al ESC Guidelines of The Task Force on VHD. Vahanian et al. EHJ 2007;28:230-267 In patients with severe AS and severe CAD, AVR with concomitant CABG provides a lower mortality. However, combined surgery carries a higher risk than isolated valve replacement in patients without CAD. Thus, CABG should be combined whenever possible with valve surgery. 

CAD and TAVR

CAD and TAVI Outcome Masson, Webb et al. CCI 2010;76:165-73 136 patients with TAVI followed for 1 year. 104 patients (76.5%) had CAD. 15 had PCI 30-100 days prior to TAVI. None had early mortality. Complete or incomplete revascularization did not change outcome. 30 day mortality 6.3% (no CAD) and 11.5% (yes CAD), p=ns. No difference in LV improvement, MR decrease of NYHA class.

CAD and TAVI Outcome Masson, Webb et al. CCI 2010; 76:165-73 These data suggest that short term outcome is not altered by underlying CAD

TAVI and CAD Masson, Webb et al. CCI 2010;76:165-73 Conclusion: The presence of CAD or nonrevascularized myocardium was not associated with an increased risk of adverse events. Complete revascularization may not constitute a prerequisite of TAVI.

CAD and TAVR Dewey et al. Ann Thor Surg g 2010;89:758-67 171 patients enrolled in the TAVR Partner Trial

CAD and TAVR Dewey et al. Ann Thor Surg g 2010;89:758-67 TF

CAD and TAVR Dewey et al. Ann Thor Surg g 2010;89:758-67 Patients with CAD constitute a higher-risk cohort: - higher logistic EuroSCOREs, - lower EF, - larger LV end diastolic volumes, - more significant mitral regurgitation. - more strokes (increase atherosclerotic burden?) Deaths: 11/12 30-day deaths were in patients with CAD. TA group: no 30 d death in patients without CAD.

Coronary Revascularization preparing for TAVI

CAD and TAVI. Gautier et al. Eurointerv 2011;7:549-55 230 patients with TAVI: 63% had CAD CAD patients had higher risk: Euroscore 31 vs 23%. More carotid stenosis 34 vs 9% >2 comorbidities 70 vs 50% 67 patients with 1 or more CAD: 11 patients had PCI (2 during TAVI). 56 had no revascularization. No periprocedural Q wave MI

Outcome of TAVI and CAD. Gautier et al. EuroInterv 2001;7:549-55 No CAD B. Similar survival and symptomatic status for CAD patients with or without revascularization.

167 with CAD: 59 had PCI (23 staged, 36 concomitant). Coronary Revascularization in TAVI Wenawesser et al. EuroInterv 2011;7:541-8 256 TAVI patients. 167 with CAD: 59 had PCI (23 staged, 36 concomitant).

Complete vs. Incomplete Revascularization No CAD

Coronary Revascularization in TAVI Wenawesser et al Coronary Revascularization in TAVI Wenawesser et al. EuroInterv 2011;7:541-8 Conclusions: Staged or concomitant PCI is feasible and safe in TAVI. Complete or incomplete revascularization of CAD does not appear to alter mid-term survival.

FFR in Severe AS Severe AS with LVH has reduced or “exhausted” coronary vascular reserve. Severe AS often has increased diastolic pressures in the LV. Both conditions could lead to a false negative FFR. Pichard et al. Am J Cardiol 1981; 47:547

How do I look at this data? Stable CAD may do well once the hemodynamic burden of severe AS is removed. Progression of CAD or plaque instability could bring on AMI, angina or SD. Hemodynamic instability (ie., ↓ BP) in the presence of untreated severe CAD may have higher mortality.

Conclusions Major territories of ischemia should be revascularized. It seems prudent and safe to do it in a staged manner. Concomitant TAVR and PCI is possible, but needs further evaluation before widespread recommendation.

The end